| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues, net | 2,675,321 | - | 3,220,556 | - |
| Cost of product and service sold | 1,554,579 | - | 1,646,575 | 1,568,188 |
| Marketing, general and administrative | 1,107,395 | - | 1,162,137 | 1,099,254 |
| Research and development | 216,098 | - | 155,940 | 140,859 |
| Total costs and expenses | 2,878,072 | - | 2,964,652 | 2,808,301 |
| Revenue, net | - | - | - | 2,781,346 |
| Loss from operations | -202,751 | - | 255,904 | -26,955 |
| Other nonoperating income (expense) | -32,797 | - | - | - |
| Interest expense, debt | - | - | 4,883 | 5,262 |
| Interest expense, nonoperating | 4,304 | - | - | - |
| Undistributed earnings (loss) allocated to participating securities, basic | - | 123,323 | 110,327 | - |
| Total other (expense) income | -37,101 | - | - | -5,262 |
| Other nonoperating expense | - | - | 5,000 | - |
| Preferred stock dividends, income statement impact | - | 12,689 | 12,970 | 12,970 |
| Income tax expense (benefit) | 0 | - | - | - |
| Net loss | -239,852 | 271,472 | 246,021 | -32,217 |
| Less income allocated to convertible preferred stocks | 13,006 | - | - | - |
| Net loss applicable to common stockholders | -252,858 | 135,460 | 122,724 | -45,187 |
| Earnings (loss) per share, basic | -0.03 | 0.02 | 0.02 | -0.01 |
| Earnings (loss) per share, diluted | -0.03 | 0.02 | 0.02 | -0.01 |
| Weighted average shares - basic | 7,415,329 | 7,415,329 | 7,415,329 | 7,415,329 |
| Weighted average shares - diluted | 7,415,329 | 14,166,217 | 14,081,616 | 7,415,329 |
ESCALON MEDICAL CORP (ESMC)
ESCALON MEDICAL CORP (ESMC)